Cargando…
Future Therapies of Wet Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population, and the prevalence of the disease increases exponentially with every decade after the age of 50 years. While VEGF inhibitors are promising drugs for treating patients with ocular neovascularization, t...
Autores principales: | Ishikawa, Makoto, Jin, Daisuke, Sawada, Yu, Abe, Sanae, Yoshitomi, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354726/ https://www.ncbi.nlm.nih.gov/pubmed/25802751 http://dx.doi.org/10.1155/2015/138070 |
Ejemplares similares
-
Long-term results after limited macular translocation surgery for wet age-related macular degeneration
por: Oshima, Hisaaki, et al.
Publicado: (2017) -
Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015) -
Imaging of Wet Age-Related Macular Degeneration
por: Kenan, Damer
Publicado: (2016) -
Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration
por: Wu, Tony, et al.
Publicado: (2023) -
Pegaptanib in the treatment of wet, age-related macular degeneration
por: Vinores, Stanley A
Publicado: (2006)